First Patient in Japan Dosed for MRCT Ph 3 Study on First-Line mCRC of Serplulimab
“The company is continuing to explore immuno-oncology therapy for mCRC, with the goal of delivering highly effective treatment for a broad population of patients. ASTRUM-015 trial is a phase 2/3 study of HANSIZHUANG (serplulimab) plus bevacizumab and chemotherapy as first-line treatment for patients with mCRC. The results of the phase 2 stage of ASTRUM-015 were presented at the 2024 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) and 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. Recently, the results were also published online in Med, demonstrating the global recognition of serplulimab by the community. In conclusion, the addition of serplulimab to bevacizumab and chemotherapy conferred a numerically longer median progression-free survival, along with a manageable safety profile for mCRC patients as a whole, and those with MSS mCRC. These results support serplulimab plus bevacizumab and chemotherapy as a promising first-line treatment option for mCRC that warrants further investigation.”
Share:
More News
Taiho Oncology, Inc. completed a New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) for zipalertinib in combination with platinum-based chemotherapy for the treatment of patients with previously untreated, locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20
“This collaboration reflects our conviction that atebimetinib has the potential to become an essential backbone therapy in a broad range of combinations across MAPK-driven cancers,” said Ben Zeskind, Immuneering CEO and co-founder. “Atebimetinib’s unique tolerability profile and broad activity make it well suited to combine with a wide range of
“These final updated results provide continued evidence of the potential for γδ T cell therapies to drive activity and improve outcomes for patients,” said William Ho, CEO and co-founder of IN8bio. “The clinical outcomes and observed activity are supported by our correlative analysis, including histopathology, demonstrating the expansion and persistence
“Patients with RAS-mutated mCRC have no first-line therapies specifically approved for their disease, and Fast Track designation reflects the potential of onvansertib to address this serious unmet need,” said Mani Mohindru, PhD, President and Chief Executive Officer of Cardiff Oncology. “Our randomized Phase 2 data give us confidence that onvansertib